Imaging in cell-based therapy for neurodegenerative diseases

被引：2
作者：
Deniz Kirik
Nathalie Breysse
Tomas Björklund
Laurent Besret
Philippe Hantraye
机构：
[1] Lund University,Section for Neuroscience, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Disease Modeling Group
[2] Service Hospitalier Frédéric Joliot,URA CEA CNRS 2210 Isotopic Imaging UIIBP Unit and Program Imagene
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2005年 / 32卷
关键词：
Parkinson’s disease; Huntington’s disease; Cell transplantation; Positron emission tomography; Magnetic resonance imaging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fetal cell transplantation for the treatment of Parkinson’s and Huntington’s diseases has been developed over the past two decades and is now in early clinical testing phase. Direct assessment of the graft’s survival, integration into the host brain and impact on neuronal functions requires advanced in vivo neuroimaging techniques. Owing to its high sensitivity, positron emission tomography is today the most widely used tool to evaluate the viability and function of the transplanted tissue in the brain. Nuclear magnetic resonance techniques are opening new possibilities for imaging neurochemical events in the brain. The ultimate goal will be to use the combination of multiple imaging modalities for complete functional monitoring of the repair processes in the central nervous system.
引用
收藏
页码：S417 / S434
相关论文
共 619 条
[1]  
Tanner CM(1999)Epidemiology of Parkinson’s disease Adv Neurol 80 153-159
[2]  
Ben-Shlomo Y(2004)Economic evidence in Parkinson’s disease: a review Eur J Health Econ 5 S63-S66
[3]  
Lindgren P(2004)Molecular pathways to neurodegeneration Nat Med 10 S2-S9
[4]  
Bossy-Wetzel E(2003)Genes and parkinsonism Lancet Neurol 2 221-228
[5]  
Schwarzenbacher R(2002)Occupational and environmental risk factors for Parkinson’s disease Parkinsonism Relat Disord 8 297-309
[6]  
Lipton SA(2003)The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2 531-538
[7]  
Hardy J(2000)Levodopa motor complications in Parkinson’s disease Trends Neurosci 23 S2-S7
[8]  
Cookson MR(1998)An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. American Academy of Neurology Neurology 50 S1-S57
[9]  
Singleton A(1997)Parkinson’s disease: clinical features Baillieres Clin Neurol 6 1-13
[10]  
Lai BC(2004)Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions J Neural Transm 111 1287-1301
12345678910